17
Participants
Start Date
January 25, 2023
Primary Completion Date
November 20, 2025
Study Completion Date
September 6, 2026
Apremilast
Oral tablets
Nagoya City University Hospital, Nagoya
Fukuoka University Hospital, Fukuoka
Hospital of the University of Occupational and Environmental Health, Japan, Kitakyushu-shi
Kurume University Hospital, Kurume-shi
Fukushima Medical University Hospital, Fukushima
Gifu University Hospital, Gifu
Gunma University Hospital, Maebashi
Takagi Dermatological Clinic, Obihiro-shi
Hokkaido University Hospital, Sapporo
Kanazawa Medical University Hospital, Kahoku-gun
Takeoka Dermatology Clinic, Marugame-shi
Takamatsu Red Cross Hospital, Takamatsu
Saruwatari Dermatology Clinic, Kagoshima
Tokai University Hospital, Isehara-shi
St Marianna University Hospital, Kawasaki-shi
University Hospital Kyoto Prefectural University of Medicine, Kyoto
Shinshu University Hospital, Matsumoto-shi
Nagasaki University Hospital, Nagasaki
University of the Ryukyus Hospital, Ginowan-shi
Kansai Medical University Hospital, Hirakata-shi
Nippon Life Hospital, Osaka
Kindai University Hospital, Osakasayama-shi
Dokkyo Medical University Hospital, Shimotsuga-gun
Sugai Dermatology Park Side Clinic, Utsunomiya
St Lukes International Hospital, Chuo-ku
Teikyo University Hospital, Itabashi-ku
Mita Dermatology Clinic, Minato-ku
Seibo International Catholic Hospital, Shinjuku-ku
Tokyo Medical University Hospital, Shinjyuku-ku
Lead Sponsor
Amgen
INDUSTRY